Skip to main
GMED

Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical (GMED) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 42%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Globus Medical is poised for growth, driven by faster-than-expected expansion in the spine market and solid performance in its Enabling Technologies segment, with Nevro sales projected to improve sequentially and contribute significantly to revenue. The company is expected to experience strong free cash flow and enhanced balance sheet flexibility, positioning it for organic growth and potential revenue guidance upside. Furthermore, as Globus Medical completes the integration of NuVasive and optimizes manufacturing processes, anticipated gross margin expansion should stabilize EBITDA margins around 34-35% in 2026, reinforcing the positive outlook for the company's financial performance.

Bears say

Globus Medical faces a notably negative outlook primarily due to anticipated slower growth in the spine market, which is crucial for its revenue generation, as well as potential disruptions stemming from recent mergers involving NuVasive and Nevro. The company's bear case scenario suggests an expectation of revenue growth declining to low single digits, alongside flat margins, indicating a challenging financial environment. Additionally, various risks, such as delayed product launches, increased competition in the musculoskeletal space, and unfavorable changes in reimbursement, further underscore the uncertainties surrounding the company's future financial performance.

Globus Medical (GMED) has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 42% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Globus Medical (GMED) Forecast

Analysts have given Globus Medical (GMED) a Buy based on their latest research and market trends.

According to 12 analysts, Globus Medical (GMED) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $99.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $99.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Globus Medical (GMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.